written articles
Last week, the field of cancer immunotherapy reached a pretty exciting milestone with Allogene Therapeutics’ publication of Phase 1 results from their ALPHA/ALPHA2 trials, which evaluated cema-cel, their allogeneic CD19-targeting CAR T-cell therapy, in patients with relapsed/refractory large B cell lymphoma (r/r LBCL). Here’s what you need to know.
Last week, the field of cancer immunotherapy reached a pretty exciting milestone with Allogene Therapeutics’ publication of Phase 1 results from their ALPHA/ALPHA2 trials, which evaluated cema-cel, their allogeneic CD19-targeting CAR T-cell therapy, in patients with relapsed/refractory large B cell lymphoma (r/r LBCL). Here’s what you need to know.
This week, AbbVie made headlines by announcing a collaboration with Xilio Therapeutics to develop tumor-activated T cell engagers. The deal includes $52 million upfront and up to $2.1 billion in potential milestone payments. Let’s break down why this partnership is significant and how it might overcome long-standing challenges in solid tumor immunotherapy.
NKGen Biotech had a breakthrough week with the FDA granting Fast Track designation to their NK cell therapy, troculeucel, for moderate Alzheimer’s disease, alongside Phase 1 results showing 90% of patients experienced stable or improved outcomes.
Oncoleader Articles Subscribe to the newsletter Get emailed whenever a new video, article, or course is released. This gives you instant access to all of our fresh content. Subscribe Orca Bio is a late-stage biotechnology company developing “precision” cell therapies…
